Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Anti-VEGF therapy assisted phacoemulsification in patients with age-related macular degeneration

Poster Details

First Author: D.Merkushenkova RUSSIA

Co Author(s):    S. Anisimova   S. Anisimov   P. Shaldin              

Abstract Details


Combination of cataract and wet age-related macular degeneration (AMD) requires to choose phacoemilsification or anti-VEGF therapy as the first stage of treatment. Isolated phaco or anti-VEGF therapy in patients with combined pathology does not result in sufficient visual outcome. Intravitreal injection of ranibizumab is possible at the end stage of phacoemulsification or can be delayed. The purpose of our study was to compare clinical results of phacoemulsification combined with simultaneous or delayed anti-VEGF therapy in patients with wet AMD.


Eye center, East Sight recovery, Moscow, Russia


45 patients (45 eyes) were involved in the study. 15 patients (15 eyes) underwent phacoemulsification with simultaneous ranibizumab injection, 15 patients (15 eyes) phacoemulsification with delayed ranibizumab injection (>1 month). 15 patients (15 eyes) who had no AMD underwent just phacoemulsification. Subjective (best corrected visual acuity, BCVA) and objective (central retinal thickness, CRT) data was evaluated at baseline and in 1, 3 and 6 months.


In one month BCVA was sighnificantly higher in patients after simultaneous phacoemulsification and ranibizumab compared to delayed ranibizumab injection (0,6±0,1 и 0,4±0,05 respectively, p<0,05). In patients without AMD BCVA was 0,9±0,1. CTR was less in simultaneous phacoemulsification and ranibizumab group then in delayed ranibizumab group (254,9±22,1 and 348,2±12,3 µm respectively, p<0,05). In patients without AMD CTR was 233,8±22,1 µm. In six month BCVA in simultaneous phacoemulsification and ranibizumab group was 0,7±0,1, CRT 263,7±13,9 µm and in “delayed” group BCVA was 0,55±0,08, CRT 270,1±14,3 µm. In patients without AMD BCVA and CRT was 0,95±0,1 and 240,2±18,1 µm respectively.


Simultaneous phacoemulsification and anti-VEGF therapy in patients with wet AMD leads to better visual outcome then delayed ranibizumab injection while mean central retinal thicknesses are matched .

Financial Disclosure:


Back to Poster listing